A Phase Ib/II Study of Ipatasertib (GDC-0068) or Apitolisib (GDC-0980) With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Trial Profile

A Phase Ib/II Study of Ipatasertib (GDC-0068) or Apitolisib (GDC-0980) With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Apitolisib (Primary) ; Ipatasertib (Primary) ; Abiraterone acetate; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms A. MARTIN study
  • Sponsors Genentech
  • Most Recent Events

    • 23 Jul 2018 Results published in the Clinical Cancer Research.
    • 21 Apr 2018 This trial has been completed in Spain.
    • 10 Feb 2018 Results assessing the associations between cancer immunity related biomarkers and PTEN loss in mCRPC samples, presented at the 2018 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top